RU2019109719A - Конъюгаты полимиксин-альгинатных олигомеров - Google Patents

Конъюгаты полимиксин-альгинатных олигомеров Download PDF

Info

Publication number
RU2019109719A
RU2019109719A RU2019109719A RU2019109719A RU2019109719A RU 2019109719 A RU2019109719 A RU 2019109719A RU 2019109719 A RU2019109719 A RU 2019109719A RU 2019109719 A RU2019109719 A RU 2019109719A RU 2019109719 A RU2019109719 A RU 2019109719A
Authority
RU
Russia
Prior art keywords
polymyxin
alginate oligomer
conjugate
antibiotic
alginate
Prior art date
Application number
RU2019109719A
Other languages
English (en)
Russian (ru)
Other versions
RU2019109719A3 (https=
Inventor
Элейн ФЕРГЮСОН
Дэвид Уильям ТОМАС
Арне ДЕССЕН
Филип РИЕ
Original Assignee
АльгиФарма АС
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1617860.0A external-priority patent/GB201617860D0/en
Priority claimed from GBGB1714710.9A external-priority patent/GB201714710D0/en
Application filed by АльгиФарма АС filed Critical АльгиФарма АС
Publication of RU2019109719A publication Critical patent/RU2019109719A/ru
Publication of RU2019109719A3 publication Critical patent/RU2019109719A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
RU2019109719A 2016-10-21 2017-10-20 Конъюгаты полимиксин-альгинатных олигомеров RU2019109719A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1617860.0A GB201617860D0 (en) 2016-10-21 2016-10-21 Polymyxin-alginate oligomer conjugates
GB1617860.0 2016-10-21
GBGB1714710.9A GB201714710D0 (en) 2017-09-13 2017-09-13 Polymyxin-alginate oligomer conjugates
GB1714710.9 2017-09-13
PCT/EP2017/076927 WO2018073449A1 (en) 2016-10-21 2017-10-20 Polymyxin-alginate oligomer conjugates

Publications (2)

Publication Number Publication Date
RU2019109719A true RU2019109719A (ru) 2020-11-24
RU2019109719A3 RU2019109719A3 (https=) 2021-02-20

Family

ID=60186268

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019109719A RU2019109719A (ru) 2016-10-21 2017-10-20 Конъюгаты полимиксин-альгинатных олигомеров

Country Status (13)

Country Link
US (1) US20190328833A1 (https=)
EP (1) EP3528830B1 (https=)
JP (1) JP2020503253A (https=)
KR (1) KR20190072579A (https=)
CN (1) CN109843315A (https=)
AU (1) AU2017345295A1 (https=)
BR (1) BR112019007927A2 (https=)
CA (1) CA3040795A1 (https=)
DK (1) DK3528830T3 (https=)
ES (1) ES2933983T3 (https=)
FI (1) FI3528830T3 (https=)
RU (1) RU2019109719A (https=)
WO (1) WO2018073449A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230104323A1 (en) * 2019-12-14 2023-04-06 Manu Chaudhary Formulations of polybasic drugs to reduce multi-organ toxicity
WO2021150792A1 (en) * 2020-01-21 2021-07-29 Micurx Pharmaceuticals, Inc. Novel compounds and composition for targeted therapy of kidney-associated cancers
US12037631B2 (en) * 2020-10-06 2024-07-16 City University Of Hong Kong System and method for detecting a target enzyme
CN113069556B (zh) * 2021-04-12 2022-04-08 青岛大学附属医院 一种枝接那他霉素的氧化海藻酸纤维膜及其制备方法
CN113081956A (zh) * 2021-04-12 2021-07-09 青岛大学附属医院 一种氧化海藻酸钠改性的那他霉素滴眼液及其制备方法
JP7755347B2 (ja) * 2021-07-21 2025-10-16 シャンハイ ミクウルク ファーマシューティカル シーオー.エルティーディー 腎癌の標的治療のための新規化合物及び組成物
EP4373836A4 (en) * 2021-07-21 2025-10-22 Shanghai Micurx Pharmaceutical Co Ltd COMPOUNDS AND COMPOSITIONS FOR TARGETED THERAPY OF KIDNEY DISEASES
CN114009731B (zh) * 2021-11-05 2024-01-02 恒枫食品科技有限公司 一种茶风味基料及其制备方法、应用
CN114752535A (zh) * 2022-05-16 2022-07-15 北京昊峰节能环保科技有限公司 一种总石油烃污染地下水生物修复剂及其制备方法与应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB976301A (en) * 1960-10-27 1964-11-25 Calmic Ltd Preparation and use of alginates
MY104520A (en) * 1989-11-15 1994-04-30 Novartis Ag Polymyxin conjugates.
US5177059A (en) * 1989-11-15 1993-01-05 Sandoz Ltd. Polymyxin B conjugates
GB2270920B (en) * 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
US6011008A (en) * 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
KR101690631B1 (ko) * 2007-11-27 2017-01-09 알지파마 아이피알 에이에스 바이오필름 퇴치에 있어서의 알기네이트 올리고머의 용도
BRPI1011248A2 (pt) * 2009-06-03 2016-03-22 Algipharma As métodos in vitro ou ex vivo de superação de resitência a pelo menos um antibiótico, para combate de contaminação de um sítio e melhora da eficácia de um antibiótico de macrolídeo para inibir o crescimento de bactéria mdr gram negativa, uso de um oligômero de alginato e produto

Also Published As

Publication number Publication date
KR20190072579A (ko) 2019-06-25
EP3528830A1 (en) 2019-08-28
JP2020503253A (ja) 2020-01-30
CN109843315A (zh) 2019-06-04
ES2933983T3 (es) 2023-02-15
RU2019109719A3 (https=) 2021-02-20
US20190328833A1 (en) 2019-10-31
CA3040795A1 (en) 2018-04-26
DK3528830T3 (da) 2022-12-19
FI3528830T3 (fi) 2023-01-13
EP3528830B1 (en) 2022-10-05
WO2018073449A1 (en) 2018-04-26
BR112019007927A2 (pt) 2019-07-02
AU2017345295A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
RU2019109719A (ru) Конъюгаты полимиксин-альгинатных олигомеров
RU2019109728A (ru) Конъюгаты бацитрацин-альгинатный олигомер
JP2020503253A5 (https=)
JP2019535669A5 (https=)
EP2641605B1 (en) Polymer derivative of cytidine metabolism antagonist
CN102688498B (zh) 紫杉烷类药物-羧甲基壳聚糖两亲性大分子前药、胶束制剂和冻干胶束制剂,及其制备方法
KR20120057588A (ko) 가변 속도 방출 링커를 포함하는 폴리알 약물 접합체
JP2019526537A5 (https=)
CN104109235A (zh) 一种具有氮原子支化中心的单一官能化聚乙二醇、制备方法及其生物相关物质
EP2806896B1 (en) Chitosan covalently linked with small molecule integrin antagonist for targeted delivery
JP2011006428A5 (https=)
MXPA04011316A (es) Derivados de camptotecina y conjugados polimericos de los mismos.
WO2007111211A1 (ja) タキサン類の高分子結合体
TW200936153A (en) Short fatty acid tail polymyxin derivatives and uses thereof
CN107660210B (zh) 基于硼替佐米的递送系统
CN101780281B (zh) N-精氨酸壳聚糖作为透皮吸收促进剂的应用
CN1203071C (zh) 谷氨酸n-衍生物的多糖酯
CN101759812A (zh) 一种新型仿穿膜肽结构的壳聚糖衍生物
ITMI20071341A1 (it) Derivati di acido ialuronico contenenti gruppi in grado di rilasciare no
JP2010533233A (ja) 芳香族アリル酸を含むポリマー性薬剤送達システム
CN106986955B (zh) 一种肝素的叠氮化修饰方法和叠氮化肝素及应用
WO2018110366A1 (ja) pH応答性ポリマー及び薬物送達システム
CN118488854A (zh) 作为抗covid-19试剂的自组装两亲性聚合物
CN1319537C (zh) 一种含甘草酸药物的纳米胶囊及其制备方法
Bilkova et al. Recent advances in the design and synthesis of prednisolone and methylprednisolone conjugates